Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Developing antibodies for targeting immunoglobulin and membrane-bound immunoglobulin E.

Tse Wen Chang1

  • 1Department of Life Science, National Tsing Hua University, Hsinchu 300, Taiwan, ROC. twchang@gate.sinica.edu.tw

Allergy and Asthma Proceedings
|May 26, 2006
PubMed
Summary

Anti-immunoglobulin E (IgE) antibodies represent a significant advancement in treating allergic diseases like asthma. Ongoing research explores their immunoregulatory effects and potential for long-term IgE regulation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Optimized sublingual delivery of dual fatty acid-conjugated GLP-1 receptor agonist TE-8105 produces durable efficacy in diabetic mice.

International journal of pharmaceutics·2026
Same author

TE-1146, a novel anti-CD38-antibody-lenalidomide conjugate, demonstrates potent <i>ex vivo</i> anti-myeloma activity.

Haematologica·2025
Same author

2FA-Platform Generates Dual Fatty Acid-Conjugated GLP-1 Receptor Agonist TE-8105 with Enhanced Diabetes, Obesity, and NASH Efficacy Compared to Semaglutide.

Journal of medicinal chemistry·2025
Same author

An Antibody-Drug Conjugate for Multiple Myeloma Prepared by Multi-Arm Linkers.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2024
Same author

Structural basis for selective inhibition of immunoglobulin E-receptor interactions by an anti-IgE antibody.

Scientific reports·2018
Same author

Bispecific Antibody Binding To RANKL and Osteonectin with Enhanced Localization to the Bone.

Molecular pharmaceutics·2017

Area of Science:

  • Immunology
  • Allergy Research
  • Pharmacology

Background:

  • Anti-immunoglobulin E (IgE) antibody development for allergic diseases spans two decades.
  • Current therapeutic anti-IgE antibodies are approved for allergic asthma, with broader applications under development.
  • These antibodies are products of rational drug design and antibody engineering, considering IgE structure.

Purpose of the Study:

  • To review the development and applications of therapeutic anti-IgE antibodies.
  • To discuss the unique binding properties and pharmacologic effects of anti-IgE.
  • To highlight the impact of anti-IgE on understanding IgE's role in allergic pathogenesis.

Main Methods:

  • Review of scientific literature on anti-IgE antibody development and clinical studies.

Related Experiment Videos

  • Analysis of the structural and functional characteristics of therapeutic anti-IgE.
  • Examination of IgE's role in allergic responses and immune defense.

    • Main Results:

    • Therapeutic anti-IgE antibodies bind free IgE and membrane-bound IgE (mIgE) but not receptor-bound IgE.
    • These antibodies are effective in allergic conditions mediated by IgE.
    • Human studies have clarified IgE's role in asthma pathogenesis and allergic reactions.

    Conclusions:

    • Therapeutic anti-IgE antibodies offer a targeted approach to managing IgE-mediated allergic diseases.
    • Further research into membrane-bound IgE (mIgE) and anti-CepsilonmX antibodies may unlock long-term IgE regulation strategies.
    • Anti-IgE antibodies possess undiscovered immunoregulatory effects warranting continued investigation.